Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial

Blood

Volumn 94, Issue 4, 1999, Pages 1218-1225

  Facon, Thierry ^a   Harousseau, Jean Luc ^b   Maloisel, Frédéric ^b   Attal, Michel ^b   Odriozola, Jesus ^b   Alegre, Adrian ^b   Schroyens, Wilfried ^b   Hulin, Cyrille ^b   Schots, Rik ^b   Marin, Pedro ^b   Guilhot, François ^b   Granena, Albert ^b   De Waele, Marc ^b   Pigneux, Arnaud ^b   Méresse, Valérie ^b   Clark, Peter ^b   Reiffers, Josy ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ANTINEOPLASTIC ACTIVITY; APHERESIS; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033567079     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.4.1218.416k06_1218_1225     Document Type: Article

References (32)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91, 1996
2. Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997
3. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 89:2233, 1997
4. Sheridan WP, Begley CG, Juttner CA, Szer J, Bikto L, Maher D, McGrath K, Morstyn, Fox R: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 339:640, 1992
5. Henry JM, Sykes PJ, Brisco MH, To LB, Juttner CA, Morley AA: Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 92:614, 1996
6. Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Monconduit M, Fuzibet JG, Caillot D, Dorvaux V, Harousseau JL, Cahn JY, Grosbois B, Stoppa AM, Ifrah N, Sotto JJ, Pignon B, Bataille R: Single versus double transplant in myeloma: A randomized trial of the "Intergroupe Français du Myélome" (IFM). Blood 90:418a, 1997 (abstr, suppl 1)
7. Demuynck H, Delforge M, Verhoef G, Zachée P, Vandenberghe P, Boogaeerts M: Comparative study of peripheral progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 90:384, 1995
8. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Alkinson T, Reading C, Hoffman R, Barlogie B: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 91:4489, 1998
9. + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 4:84, 1998
10. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825, 1994
11. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34+ content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961, 1995
12. Bernstein ID, Andrews RG, Zsebo KM: Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin-cells, and the generation of colony-forming cell progeny from CD34+ lin-cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 77:2316, 1991
13. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19:226, 1991
14. Briddell RA, Hartley CA, Smith KA, McNiece IK: Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 82:1720, 1993
15. McNiece IK, Briddell RA, Hartley CA, Smith KA, Andrews RG: Stem cell factor enhances in vivo effects of granulocyte colony stimulating factor for stimulating mobilization of peripheral blood progenitor cells. Stem Cells 11:36, 1993 (suppl 2)
16. De Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J, McNiece IK, Andrews RG, Graham T: Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 83:3795, 1994
17. Andrews R, Briddell R, Knitter G, Opie T, Bronsden M, Myerson D, Appelbaum FR, McNiece IK: In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons: Enhanced circulation of progenitor cells. Blood 84:800, 1994
18. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker W, Glaspy JA: A randomized phase 3 study of PBPC mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93:2431, 1999
19. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L: Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939, 1997
20. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J: Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients. Results of a phase I/II trial. Blood 89:3136, 1997
21. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Olson E, Wyres M, Parker W, Barlogie B: Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHuSCF (SCF) and r-metHuG-CSF (filgrastim) in heavily pretreated multiple myeloma (MM) patients. Blood 88:388a, 1996 (abstr, suppl 1)
22. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323, 1996
23. Weaver A, Testa NG: Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy. Bone Marrow Transplant 22:33, 1998
24. Begley CG, Basser R, Mansfield R, Thomson B, Parker WRL, Layton J, To B, Cebon J, Sheridan WP, Fox RM, Green MD: Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 90:3378, 1997
25. Stiff P, Gingrich R, Luger S, Brown RA, LeMaistre CF, Perry J, Schenkein D, List A, Mason JR, Bensinger W, Wheeler CA, Freter C, Murphy-Filkins R, Wyres M, Parker W, Emmanouilides C: Improved PBPC collection using Stemgen® (stem cell factor) and filgrastim (G-CSF) compared to G-CSF alone in heavily pretreated lymphoma and Hodgkin's disease patients. Blood 90:591a, 1997 (abstr, suppl 1)
26. Goldberg SL, Mangan KF, Klumpp TR, MacDonald JS, Thomas C, Mullaney MT, Au FC: Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 4:85, 1995
27. Glaspy J, Snyder C, Lu J, Erder MH: A resource-based cost analysis of GCSF-primed peripheral blood progenitor cell procurement (PBPCP). Proc Am Soc Clin Oncol 16:412a, 1997 (abstr)
28. Ossenkoppele GJ, Schuurhuis GJ, Jonkhoff AR, Dräger AM, Westra G, Oberink JW, Legdeur MCJC, de Kreuk AM, Zweegman S, Huijgens PC: G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a BEAM-like regimen in bad-risk lymphoma. Bone Marrow Transplant 18:427, 1996
29. Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, Schmitz N: autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cells but not of bone marrow grafts. Blood 86:3970, 1995
30. Weaver CH, Birch R, Schuman KA: effect of cell dose on ressource utilization in patient undergoing transplant with peripheral blood progenitor cells. Blood 90:370a, 1997 (abstr, suppl 1)
31. Barlogie B, Jagannath S, Vesole, DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowled J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997
32. Moore MAS: Expansion of myeloid stem cells in culture. Semin Hematol 32:183, 1995